Abstract
Get full access to this article
View all access options for this article.
References
1.
Wang
JR
,
Zafereo
ME
,
Dadu
R
,
Ferrarotto
R
,
Busaidy
NL
,
Lu
C
,
Ahmed
S
,
Gule-Monroe
MK
,
Williams
MD
,
Sturgis
EM
,
Goepfert
RP
,
Gross
ND
,
Lai
SY
,
Gunn
GB
,
Phan
J
,
Rosenthal
DI
,
Fuller
CD
,
Morrison
WH
,
Iyer
P
,
Cabanillas
ME
. 2019 . Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E -mutated anaplastic thyroid carcinoma . Thyroid , 29 :1036 –1043 .
2.
Subbiah
V
,
Cabanillas
ME
,
Kreitman
RJ
,
Wainberg
ZA
,
Cho
JY
,
Keam
B
,
Schellens
JHM
,
Soria
JC
,
Wen
PY
,
Zielinski
C
,
Urbanowitz
G
,
Mookerjee
B
,
Wang
D
,
Rangwala
F
. 2018 . Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer . J Clin Oncol , 36 :7 –13 .